GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (STU:82P) » Definitions » Cyclically Adjusted PB Ratio

Pacira BioSciences (STU:82P) Cyclically Adjusted PB Ratio : 2.46 (As of Jun. 09, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Pacira BioSciences Cyclically Adjusted PB Ratio?

As of today (2024-06-09), Pacira BioSciences's current share price is €26.20. Pacira BioSciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €10.66. Pacira BioSciences's Cyclically Adjusted PB Ratio for today is 2.46.

The historical rank and industry rank for Pacira BioSciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:82P' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.21   Med: 8.96   Max: 59.96
Current: 2.4

During the past years, Pacira BioSciences's highest Cyclically Adjusted PB Ratio was 59.96. The lowest was 2.21. And the median was 8.96.

STU:82P's Cyclically Adjusted PB Ratio is ranked worse than
57.95% of 742 companies
in the Drug Manufacturers industry
Industry Median: 1.875 vs STU:82P: 2.40

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Pacira BioSciences's adjusted book value per share data for the three months ended in Mar. 2024 was €17.645. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €10.66 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pacira BioSciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Pacira BioSciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacira BioSciences Cyclically Adjusted PB Ratio Chart

Pacira BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.24 10.52 8.01 4.12 3.00

Pacira BioSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.13 3.87 2.83 3.00 2.46

Competitive Comparison of Pacira BioSciences's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Cyclically Adjusted PB Ratio falls into.



Pacira BioSciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Pacira BioSciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=26.20/10.66
=2.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Pacira BioSciences's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=17.645/131.7762*131.7762
=17.645

Current CPI (Mar. 2024) = 131.7762.

Pacira BioSciences Quarterly Data

Book Value per Share CPI Adj_Book
201406 3.039 100.560 3.982
201409 3.341 100.428 4.384
201412 3.839 99.070 5.106
201503 4.679 99.621 6.189
201506 4.753 100.684 6.221
201509 5.069 100.392 6.654
201512 5.441 99.792 7.185
201603 5.474 100.470 7.180
201606 5.452 101.688 7.065
201609 5.106 101.861 6.606
201612 5.539 101.863 7.166
201703 6.322 102.862 8.099
201706 5.762 103.349 7.347
201709 5.477 104.136 6.931
201712 5.807 104.011 7.357
201803 5.547 105.290 6.942
201806 6.072 106.317 7.526
201809 6.288 106.507 7.780
201812 6.850 105.998 8.516
201903 7.020 107.251 8.625
201906 7.267 108.070 8.861
201909 7.537 108.329 9.168
201912 7.623 108.420 9.265
202003 8.037 108.902 9.725
202006 8.089 108.767 9.800
202009 11.461 109.815 13.753
202012 11.673 109.897 13.997
202103 12.437 111.754 14.665
202106 12.835 114.631 14.755
202109 13.719 115.734 15.621
202112 14.450 117.630 16.188
202203 14.297 121.301 15.532
202206 15.628 125.017 16.473
202209 16.959 125.227 17.846
202212 15.930 125.222 16.764
202303 15.605 127.348 16.148
202306 16.069 128.729 16.449
202309 16.783 129.860 17.031
202312 17.166 129.419 17.479
202403 17.645 131.776 17.645

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pacira BioSciences  (STU:82P) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Pacira BioSciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacira BioSciences (STU:82P) Business Description

Traded in Other Exchanges
Address
5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has launched EXPAREL which utilizes DepoFoam, a product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.

Pacira BioSciences (STU:82P) Headlines

No Headlines